As such, the targeted inhibition of FGFRs has emerged as a promising anti-cancer strategy, especially in breast cancers that overexpress FGFRs and/or have developed resistance to EGFR/ErbB2-targeted therapeutics (i.e. lapatinib, trastuzumab, gefitinib, and erlotinib) through compensatory FGFR activation50–54. Here, ERBB2 is linked to breast carcinoma.